Prognosis

The prognosis for Hodgkin lymphoma is very good. After five years, 80 to 90% of all patients are still living without the disease having returned. In children, this rate is even higher with over 90% of disease-free surviving patients after five years.

Two thirds of recurrences occur in the first year after completed therapy, and over 99% within the first five years. This means that structured follow-up care in the first five years after therapy is very important to detect recurrence of the disease early. However, the risk of a second cancer is increased by therapy with multiple chemotherapeutics and radiation.

Approximately 10-20% of patients develop a second tumor in the course of their lives, often not until 30 years later. Typical second tumors are: The presence of B-symptoms indicates a worse prognosis.

Breast Cancer
Thyroid cancer
Acute myeloid leukemia

The prognosis in non-Hodgkin’s lymphomas cannot be determined universally for all subtypes of this group.

It depends largely on the behavior of the individual species. In the following, the prognosis for individual frequently occurring non-Hodgkin lymphomas is given. 1. diffuse large cell B non-Hodgkin’s lymphoma has a 5-year survival rate of 60% to 90%, depending on the genetic characteristics.

2. follicular lymphoma has a mean survival rate of about 10 years at the time of diagnosis. 3. mantle cell lymphoma has an even worse prognosis with a median survival of about 5 years. 4. the prognosis of multiple myeloma depends on many factors.

In the best case in young patients with optimal therapy the survival rate after 10 years is 50%. 5. Burkitt’s lymphoma leads to death within months if diagnosed late and treated inadequately.

If it is detected and treated early, the chance to survive the next 10 years is about 90%. If several organs are already affected at the time of diagnosis, this chance of survival drops to below 50%. Unfortunately, Burkitt’s lymphoma often has secondary tumors, which also has a negative impact on the prognosis.

6. the mycosis fungoides shows a good prognosis only in a very early stage due to a very slow growth. However, if the tumor has a cross-border growth, the prognosis is very poor. 7. the Sézary syndrome can show a favorable course over years.However, once a certain stage has been passed, the condition deteriorates very quickly, often with a fatal outcome.

High age
Poor general condition
Stages III and IV to Ann-Arbor
Infection outside the lymph nodes